Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of imatinib with two chemotherapy backbones in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia
2017-000705-20Phase 3Active
- Sponsor
- University of Barcelona
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imatinib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by University of Barcelona. Primary endpoint: Disease-free survival. Started Oct 2017; status: active.
02
Drugs
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2017-000705-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000705-20.